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Simian–human immunodeﬁciency virus encoding both reverse transcriptase (RT) and envelope genes
of HIV-1 (RT Env SHIV) is important for evaluating biomedical prevention modalities for HIV/AIDS. We
describe virological characterization of a clade B RT Env SHIV following infection of macaques via
multiple routes. In vivo passage of the RT Env SHIV through Indian rhesus macaque enhanced
infectivity. Expanded virus had minimal envelope heterogeneity and was inhibited by NNRTIs and
CCR5 antagonists. Infection of macaques with RT Env SHIV via mucosal or intravenous routes resulted
in stable infection accompanied by peak plasma viremia of approximately 5106 copies/ml that was
controlled beyond set point. Molecular homogeneity of the virus was maintained following in vivo
passage. Inhibition of RT Env SHIV by RT and entry inhibitors and ease of in vivo transmission make it a
useful model for testing the efﬁcacy of combinations of entry and RT inhibitors in nonhuman primates.
& 2012 Elsevier Inc. All rights reserved.Introduction
Mucosal transmission accounts for the majority of all HIV
infections worldwide (UNAIDS, 2010). In the absence of an
effective prophylactic HIV vaccine, antiretroviral prophylaxis
strategies that are directed toward preventing sexual transmis-
sion of HIV-1 are urgently needed. Use of vaginal microbicides
and/or oral pre-exposure prophylaxis (PrEP) to inhibit mucosal
transmission of HIV-1 may represent important strategies in
controlling the sexual transmission of HIV-1 (Cong et al., 2011;
Curtis et al., 2011; D’Cruz and Uckun, 2004; Elias and Coggins,
1996; Garcia-Lerma et al., 2011; Garcia-Lerma et al., 2008; Garg
et al., 2009; Grant et al., 2008; Klasse et al., 2008; Klasse et al.,
2006; Lederman et al., 2006; McGowan, 2010; Ramjee et al.,
2010; van de Wijgert and Shattock, 2007).
Drugs targeting RT have been used routinely to curb HIV-1
infection and have become an integral component of ARV therapy.
Oral and topical PrEP regimens targeting RT have recently been
shown to be at least partially effective in clinical trials (Abdool
Karim et al., 2010; Grant et al., 2010; Jochmans, 2008; Network,
2011; Prajapati et al., 2009; Prevention, 2011). A number of RTll rights reserved.inhibitors were shown to be more potent against HIV-1 RT than
SIV RT (Buckheit et al., 2007; Buckheit et al., 2001; Kuritzkes,
2009). Therefore, efﬁcacy of RT inhibitor-based PrEP in nonhuman
primate models is often assessed against challenges with SHIV
isolates encoding the RT gene of HIV-1. To this end, a number of
RT SHIV isolates with varying degrees of pathogenicity have been
constructed and used in challenge studies in nonhuman primates
(Ambrose et al., 2004; Ambrose et al., 2007; Balzarini et al., 1997;
Jiang et al., 2009; Pal et al., 2009; Soderberg et al., 2002). In recent
years the development of new and effective antiretroviral thera-
pies and PrEP has expanded rapidly beyond the original drugs
targeting RT, and compounds designed to inhibit both binding
and entry of HIV-1 to target cells are being investigated either
alone or in combinations with RT inhibitors (Kuritzkes, 2009).
Moreover, compounds with both entry and RT inhibitory activ-
ities are also being shown to be potent inhibitors of HIV-1 in vitro
(Balzarini et al., 1996; Buckheit et al., 2008; Fletcher et al., 2005;
Owen et al., 2004). To assess the in vivo efﬁcacy of such
compounds with dual inhibitory activities in the nonhuman
primate model, SHIV encoding both an R5-tropic Clade B HIV-1
envelope and HIV-1 RT in an SIV background was recently
constructed (Smith et al., 2010). This virus could infect rhesus
macaques intravenously and intra-rectally, and was sensitive to
selected RT and entry inhibitors. In this communication, we
describe a more detailed characterization of this RT Env SHIV
R. Pal et al. / Virology 432 (2012) 173–183174construct by using a broader range and combinations of RT and
entry inhibitors. Moreover, in vivo passage of this virus was
evaluated in nonhuman primates via the intra-vaginal route, as
well as via intravenous and intra-rectal routes. It is expected that
this new SHIV recombinant virus with stable replication kinetics
in macaques may ﬁnd widespread application in assessing the
efﬁcacy of microbicide or PrEP prophylactic regimens with dual
RT and entry inhibitory activities.Table 1
Characteristics of RT Env SHIV stocks expanded by in vivo passage through Indian
rhesus macaques.
Isolate Viral RNA copies/ml
supernatant
p27 values
(ng/ml)
TCID50 in
rPBMC
TCID50 in
TZM-bl
P241 (P2) PHA 2.36109 73 2.05102 2.86104
P244 (P3) PHA 2.92109 144 1.75103 1.15105
P244 (P3) ConA 2.37109 182 2.02103 1.15105Results
In vivo passage and expansion of RT Env SHIV
In an attempt to enhance the infectivity of RT Env SHIV, the
parental virus was successfully passaged serially in vivo through
three Indian origin rhesus macaques, P237 (P1), P241 (P2) and
P244 (P3). As illustrated in Fig. 1, blood and bone marrow were
transfused once plasma viremia reached a peak load in each
infected macaque. Macaque P244 (P3) showed a markedly higher
peak plasma viral load of 107.76 copies/ml on day 12 post
infection, when compared to that observed in animals P237
(106.73 vRNA copies/ml) and P241 (106.65 vRNA copies/ml) at a
similar time point (data not shown).
The in vitro characterization of PHA- or ConA expanded RT Env
SHIV from macaque P241 and P244 PBMC (Fig. 1) was also
performed by evaluating SIV p27 content, RNA copies and
infectious titers in rhesus macaque PBMC and TZM-bl cells. As
shown in Table 1, the two virus stocks prepared from both ConA-
or PHA-activated PBMC from macaque P244 (P3) had similar
infectious titers and p27 content but these values were markedly
higher than that observed with the virus expanded from P241
(P2) PBMC. This enhancement of infectivity of virus derived from
P244 PBMC correlated well with the higher peak plasma viremia
observed in macaque P244 which was approximately 10-fold
higher than that observed in macaque P241.
Genomic heterogeneity of expanded RT Env SHIV stocks
In order to determine the degree of diversity in env, gag, pol and
nef in the RT Env SHIV stocks following the three in vivo passages
and in vitro expansion, a total of 20 amplicons per gene were
obtained by SGA from virus stocks derived from PHA-activated and
ConA-activated P244 (P3) PBMC. Since the V1–V5 region of env is1 ml undiluted 
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Fig. 1. Schematic representation of in vitro RT Env SHIV expansion and in vivo passage
expanded as described in the text.highly variable, preliminary sequence analysis was focused on this
segment of the env gene. The diversiﬁcation of in vitro-expanded
virus was ﬁrst evaluated by comparing the genetic variation in
ConA- and PHA-derived RT Env SHIV stocks. As shown by the
Highlighter plot in Fig. 2A, the alignment of env V1–V5 sequences
with the P244 (P3) plasma virus isolate as the reference sequence,
indicates that 15 out of 20 amplicons (75%) from the ConA-derived
stock were identical, with the remaining exhibiting 1–2 nucleotide
substitutions per sequence (maximum diversity of 0.17%). In
comparison, a lower fraction (40%) of amplicons from the PHA-
derived stock exhibited identical env sequences, with the rest
consisting of 1–6 nucleotide substitutions per sequence, suggesting
a slightly higher level of genetic heterogeneity in this stock
(maximum diversity of 0.5%). The ConA-derived virus stock was
therefore selected for further analysis of env V1–V5, gag, pol and nef
diversity. A comparison of these gene sequences to the original RT
Env SHIV master stock by Highlighter analysis (Fig. 2B) revealed a
low level of genetic variation, with the maximum diversity for each
gene being less than 0.26%. The translation of env V1–V5 amplicon
sequences to their corresponding protein sequences revealed
minimal amino acid changes, with only a single amplicon exhibit-
ing two substitutions (E256K and D355N). Similarly, minor amino
acid substitutions were observed for Gag, Pol (drug resistance
mutations in the RT and protease regions were not present) and
Nef protein sequences, with two or fewer substitutions being
observed per amplicon.
Characterization of RT Env SHIV in terms of sensitivity to RT and
entry inhibitors
The function of HIV-1 reverse transcriptase and envelope
genes in the RT Env SHIV was evaluated by determining the
sensitivity of the ConA-derived expanded virus to RT and entryP244 (P3)
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Fig. 2. Highlighter plots of RT Env SHIV stocks expanded in vitro from P244 (P3) PBMC. (A) Comparison of SGA-derived env V1–V5 sequences in expanded stocks from
PHA-activated and ConA-activated P244 (P3) PBMC. Nucleotide polymorphisms are in comparison to the consensus sequence of plasma virus isolates from P244 (P3) at
peak viral load. (B) Highlighter plots of SGA-derived env V1–V5, gag, pol and nef sequences in the expanded stock from ConA-activated P244 (P3) PBMC, when compared to
the RT Env SHIV master stock sequence. Nucleotide polymorphisms are indicated by a colored tic mark (adenine in green, thymine in red, guanine in orange, and cytosine
in light blue). (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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(encoding HIV-1 R5 Env and SIV RT) and RT SHIV (encoding SIV
Env and HIV-1 RT) were also examined. CMPD167 and maraviroc
(both CCR5 antagonists), dapivirine (NNRTI) and tenofovir (NRTI)
were used as inhibitors and the assay was performed in TZM-bl
cells expressing human CCR5. Both RT Env SHIV and SHIV162P3,
which contain the same env gene of HIV-1, were markedly
inhibited by CMPD167 (Fig. 3A) and maraviroc (Fig. 3B) to a
comparable degree. On the other hand, RT SHIV encoding SIV env
gene was less sensitive to these CCR5 antagonists. All three viruses
were sensitive to tenofovir as this inhibitor targeted both HIV-1
and SIV RT (Fig. 3D), although at lower concentrations of drug,
SHIV162P3 was slightly less sensitive. While dapivirine was a
potent inhibitor of both RT SHIV and RT Env SHIV, SHIV162P3
encoding SIV RT was not inhibited by dapivirine (Fig. 3C). Since the
same dose (200 TCID50) of each virus construct was used in these
assays, the difference in sensitivity observed among the threeviruses is speciﬁc to the HIV-1/SIV gene encoded by each SHIV
construct. Thus, these results clearly demonstrate the presence of
functional HIV-1 RT and Env in the RT Env SHIV isolate.
As the two different virus stocks prepared from PHA- or
ConA-activated P244 (P3) PBMC had minor genetic heterogeneity,
both stocks were compared for equivalency by measuring their
sensitivities to entry and RT inhibitors. For these analyses CMPD167,
maraviroc, dapivirine, tenofovir and sCD4 were used as inhibitors
and the IC90 and IC50 values were determined in TZM-bl cells
(Table 2). These results suggest that although virus derived from
PHA-activated PBMC was more heterogeneous than that expanded
from Con A-activated PBMC, both stocks were equally sensitive to
the inhibitors tested, with comparable IC50 and IC90 values.
To demonstrate any synergistic effect of RT and entry inhibitors
in blocking RT Env SHIV infection, dual combinations of the RT
(dapivirine and tenofovir) and entry (CMPD167 and maraviroc)
drugs were used for inhibition of RT Env SHIV in TZM-bl cells with
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Fig. 3. Sensitivity of ConA-expanded RT Env SHIV to RT and entry inhibitors. Inhibitory activity was measured as a reduction in luciferase reporter gene expression after
a single round of infection in TZM-bl cells, in the presence of (A) CMPD167, (B) Maraviroc, (C) Dapivirine, and (D) Tenofovir. Shown for comparison are the effects of these
drugs on SHIV 162P3 (encodes HIV-1 R5 Env and SIV RT), RT SHIV (encodes SIV Env and HIV-1 RT), and RT Env SHIV (encodes HIV-1 R5 Env and HIV-1 RT).
Table 2
Comparative sensitivities of PHA- and Con A-derived RT Env SHIV stocks to entry and RT inhibitors.
Compund ConA-PBMC derived PHA-PBMC derived
IC90 IC50 IC90 IC50
Dapivirine (nM) 2.91 1.15 2.67 1.07
Tenofovir (lM) 17.22 3.87 17.56 4.15
CMPD167 (nM) 15.99 3.91 16.61 4.13
Maraviroc (nM) 75.74 29.43 85.57 27.83
sCD4 (lg/ml) 16.38 9.15 16.88 8.35
Inhibitor combinations
CMPD167þDapivirine 7.03 nM/1.32 nM 2.43 nM/0.45 nM
CMPD167þTenofovir 5.47 nM/6.84 mM 1.33 nM/1.67 mM
MaravirocþDapivirine 32.46 nM/1.30 nM 14.14 nM/0.57 nM
MaravirocþTenofovir 22.24 nM/5.93 mM 4.77 nM/1.27 mM
R. Pal et al. / Virology 432 (2012) 173–183176Con A-PBMC derived virus and the results are shown in Table 2.
Starting concentrations of drug combinations used in this assay
were selected close to the IC90 value of individual molecules
(CMPD167 16 nM, dapivirine 3 nM, tenofovir 20 mM and maraviroc
75 nM). It is clear from the IC50/IC90 values that the combinations
were highly effective in blocking viral infection. However, the
inhibitory activity was primarily additive rather than synergistic,
as the inhibitory concentrations of the individual compounds in
the drug combinations were not markedly reduced when com-
pared to their effects when applied singly. Preliminary comparative
analyses of the inhibitory concentrations of the single and dual
drug applications by Chou and Talalay’s combination index method
revealed a lack of synergistic effects with all but the tenofovir andmaraviroc combination where mild synergy was noted (Chou and
Talalay, 1984). It is to be noted that similar inhibition assays
performed in primary PBMC would extend this observation and
this will be the subject of future investigation in our laboratories.
To demonstrate whether the inhibition noted in TZM-bl cells
would also extend to primary cell targets, similar inhibition
assays were conducted with CMPD167, maraviroc and dapivirine
in PHA-activated rhesus macaque PBMC targets with PHA-derived
virus (data not shown). While dapivirine inhibited RT Env SHIV
with IC90/IC50 comparable to that observed in TZM-bl cells
(1.89 nM/0.94 nM), the entry inhibitors CMPD167 and maraviroc
had higher IC90/IC50 values (112 nM/34 nM for CMPD167 and
420 nM/119 nM for maraviroc (not shown).
Fig. 4. Plasma viral RNA loads in macaques infected with RT Env SHIV via mucosal and intravenous routes. Virus isolated from ConA-activated PBMC from macaque
P244 (P3) PBMC was inoculated intra-vaginally (IVAG, n¼4), intra-rectally (IR, n¼4), or intravenously (IV, n¼2) and plasma viral RNA load was monitored over time by
NASBA assay as described in the Materials and methods section.
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systemic routes
Given the lower level of genetic heterogeneity in virus derived
from ConA-activated PBMC, this expanded stock was used for
further in vivo characterization experiments. In vivo challenges
with RT Env SHIV via rectal (IR), vaginal (IVAG) and intravenous
(IV) routes were evaluated (Fig. 4). For vaginal infection, four
Chinese rhesus macaques were challenged once with 1 ml of
undiluted virus containing 2.02Eþ03 TCID50 (Table 1) and the
plasma viral RNA load was measured weekly over time. While
three of four animals were infected after this challenge, macaque
P341 resisted infection. However, after rechallenge vaginally with
the same dose of virus 41 day later, it became infected. Plasma
viral RNA load in each of the infected animals is shown in Fig. 4A.
While peak viremia reached high RNA loads (4106 copies/ml),
the level in each animal dropped rapidly thereafter. For assessing
infection via the rectal route, four naı¨ve Indian rhesus macaques
were similarly challenged IR with 1 ml of undiluted virus contain-
ing 2.02Eþ03 TCID50 (Table 1). As shown in Fig. 4B, all four
macaques were infected following a single exposure. Detectable
viral RNA load appeared to persist longer in the plasma of IR-
challenged animals following set point, after which time it was
controlled to levels below the assay’s detection limit. For systemic
infection, two Indian rhesus macaques were IV-challenged with1 ml of diluted virus containing 250 TCID50. A less infectious dose
was used for IV inoculation when compared to mucosal challenge
because of the ease of transmission of SHIV via the systemic
route. Both animals were infected following single administration
of virus, with viremia persisting for up to 18 weeks, although peak
viral RNA load between the two animals was variable (Fig. 4C).
Immunological responses following RT Env SHIV infection
To determine if RT Env SHIV induced virus-speciﬁc immuno-
logical responses in vivo, both humoral and cell-mediated
immune responses were evaluated in the infected rhesus maca-
ques. Although all infected animals clearly seroconverted and
developed strong anti-Env antibody responses beyond set point,
the sera that were collected at different time points post infection
were non-neutralizing against SHIV162P3, which encodes the
autologous Env present in RT Env SHIV (data not shown). To
determine whether there is a differential induction of cellular
responses to SIV and HIV-1 antigens coded by the SHIV isolate,
ELISPOT assays were conducted by isolating PBMC from the IR-
challenged Indian rhesus macaques (n¼4) on days 78 and 112
post infection, and stimulating these cells ex vivo with HIV-1 Env,
HIV-1 RT or SIVmac251Gag peptide pools. Results represent-
ing the mean responses from all these infected animals along
with the standard deviation are shown in Fig. 5. These results
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Fig. 5. Cell-mediated immune responses to SIV and HIV antigens following
infection with RT Env SHIV derived from ConA-activated PBMC of P244 (P3).
ELISPOT assays were performed using PBMC isolated from IR-infected macaques
(n¼4) on days 78 and 112 post infection. PBMC were stimulated ex vivo with HIV-
1 Env (black bars), HIV-1 RT (light grey bars) or SIVmac251 Gag (dark grey bars)
peptide pools. Shown are mean values for the 4 animals plus standard deviation.
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resulted in the induction of cell-mediated immune responses to
SIV Gag and HIV-1 Env antigens, response to polymerase antigen
was signiﬁcantly lower.
Characterization of transmitted/founder variants in animals infected
mucosally with RT Env SHIV
In order to characterize RT Env SHIV variants that were trans-
mitted via mucosal routes of infection, analysis of SGA-derived env
V1–V5 sequences was performed on virus isolates from animals that
were productively infected after a single exposure. Plasma samples
that tested positive for viral RNA at 10–14 day post-infection were
considered for analysis. As shown by the Highlighter plots in Fig. 6,
sequence analysis of env V1–V5 in variants from 3 IVAG-infected and
3 IR-infected macaques revealed low diversity (r0.33%) among
transmitted/founder variants when compared to the consensus
sequence of the Con A-derived virus stock that was used to challenge
each of the animals. Collective analysis of env V1–V5 sequences from
the ConA-derived virus stock, virus isolates from the 6 macaques, and
the RT Env SHIV master stock, further conﬁrmed a low level of
variation as shown by the composite neighbor-joining trees in Fig. 7.
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Fig. 7. Composite neighbor-joining trees of env V1–V5 sequences from the RT Env SHIV master stock, from ConA-activated P244 (P3) PBMC-derived stock, and from IVAG-
or IR-infected rhesus macaques. (A) An unrooted tree illustrating star-like phylogeny. For purposes of clarity, labeling of variants was omitted here and speciﬁed in (B) a
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ﬁgure legend, the reader is referred to the web version of this article.)
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was observed, as highlighted by isolates from IVAG-infected or IR-
infected macaques (Fig. 7B), but a combination of bootstrapping
(o70%) and Hamming distance analyses further suggested minimal
genetic heterogeneity.Discussion
Several entry and RT inhibitors are being developed for PrEP
strategies to protect from HIV-1 infection. Efﬁcacy testing of such
compounds in vivo represents an important step in the product
development pathway before these are tested for efﬁcacy in
humans. Although a positive outcome in a preclinical efﬁcacy
study may not always guarantee such an outcome in humans,
negative efﬁcacy of a given drug in preclinical trials may warrant
caution before proceeding to large-scale testing in humans. In
order to model HIV-1 infection more accurately, chimeric viruses
containing R5 HIV-1 tat, rev, vpu and env in an SIV backbone
(SHIV) have been created that are able to infect macaques of
different species (Harouse et al., 2001; Humbert et al., 2008; Pal
et al., 2003; Siddappa et al., 2009; Sina et al., 2011). Although
several of these SHIV constructs exhibit a limited capacity for
prolonged replication in vivo, this is not a limitation when
evaluating drugs for prevention of transmission or infection. Entry
inhibitors have been extensively evaluated for in vivo efﬁcacy in
the nonhuman primate model against SHIV isolates encoding
R5-tropic envelope (Kish-Catalone et al., 2007; Lederman et al.,
2004; Tsai et al., 2004; Veazey, 2008; Veazey et al., 2010; Veazey
et al., 2005; Veazey et al., 2009). Since SIV isolates are relatively
insensitive to some NNRTIs (Buckheit et al., 2007; Buckheit et al.,
2001), only a few studies have been conducted to evaluate
efﬁcacy of NNRTIs in nonhuman primates against SIV infection.
For such efﬁcacy trials and to study the mechanisms of drug
resistance in the macaque model, a number of RT SHIV isolates
have been constructed. Although some of these isolates wereshown to replicate in macaques with low efﬁciency, selective
mutation of the RT SHIV genome in the tRNA primer binding site
led to a marked increase of replication both in T-cell lines as well
as in macaques (Ambrose et al., 2004; Soderberg et al., 2002).
However, SHIV constructs encoding either HIV-1 RT or env gene
alone may not be useful to evaluate efﬁcacy of microbicide
combinations containing both entry and RT inhibitors or drugs
with dual RT and entry inhibitory activities. Previously, a SHIV
construct with both RT and env genes of HIV-1 was described but
this construct replicated poorly in vivo in macaques (Akiyama
et al., 2003). A new RT Env SHIV constructed with the env gene of
SHIV162(P3) and the RT gene of HIV-1 HXB2 was recently
developed, and was infectious in vivo (Smith et al., 2010).
However, the ability of this new SHIV to infect via various routes
as well as its susceptibility to antivirals targeting Env and RT,
particularly in combination, had not been extensively described.
Here, we show that the new RT Env SHIV is markedly inhibited
by RT and entry inhibitors in vitro both in primary rhesus PBMC
targets (data not shown) and in TZM-bl cells (Table 2). However,
the level of inhibition of viral infection between the target cells
varied. While this may be attributed to differences in the type and
level of expression of CCR5 in TZM-bl cells and primary rhesus
PBMC, the entry inhibitors CMPD167 and maraviroc were shown
to effectively inhibit RT Env SHIV infection in both target cells.
We also noted a similar pattern of inhibition of SHIV162P3
(expressing identical envelope as RT Env SHIV) in both nonhuman
primate PBMC and TZM-bl cells that were treated with maraviroc
(data not shown). Inhibition experiments conducted with other
target cells expressing different levels of human or nonhuman
primate CCR5, as well as human PBMC, may provide important
information regarding the role of CCR5 co-receptor density in RT
Env SHIV infection and this will be the subject of future investiga-
tion in our laboratories. These data collectively extend our
previous ﬁndings that demonstrated the sensitivity of RT Env
SHIV to the NRTI tenofovir, NNRTI UC781 and the entry inhibitor
T20. Combinations of RT and entry inhibitors were also potent
R. Pal et al. / Virology 432 (2012) 173–183180blockers of this virus. The degree of inhibition was primarily
additive and not synergistic. Since several of these combination
drugs are being developed for clinical trials, in vivo experiments
using the newly developed dual RT Env SHIV construct can now
be conducted to test their efﬁcacy in nonhuman primate models.
The RT Env SHIV would be particularly valuable for in vivo testing
of the efﬁcacy of antivirals such as pyrimidinediones and RC101
which have both entry and RT inhibitory activities, both alone and
in combination with more potent entry inhibitors (Balzarini et al.,
1996; Buckheit et al., 2008; Fletcher et al., 2005; Owen et al.,
2004).
We had demonstrated earlier that serial passage of SHIV in
macaques via blood and bone marrow transfer enhances viral
infectivity resulting in high plasma viremia in challenged maca-
ques (Barnett et al., 2008; Pal et al., 2003). As peak plasma viral
loads of 106 copies/ml were obtained with the RT Env SHIV in
rhesus macaques in the original study (Smith et al., 2010), we
wanted to examine whether in vivo passage would enhance its
infectivity. As described here, in vivo passage of RT Env SHIV
through three Indian rhesus macaques enhanced its infectivity as
evidenced by the approximate 10-fold increase in plasma viral
load, while not altering its tropism for CCR5 and RT speciﬁcity.
Sequence analysis of both RT and env genes revealed minimal
genetic changes following in vivo passage. However, such
changes, primarily in the env gene, may have conferred enhanced
replicative capacity in vivo. Selective cloning of env from the P244
(P3) virus isolate into the SHIV backbone would help address
whether this enhanced infectivity is indeed envelope-mediated.
The results presented here clearly demonstrate that RT Env
SHIV efﬁciently infects rhesus macaques via mucosal and sys-
temic routes, and shows for the ﬁrst time that this SHIV construct
can infect vaginally. One of the major problems encountered
when evaluating the efﬁcacy of microbicides and PrEP in pre-
venting vaginal transmission of SHIV in macaques is the reliability
and reproducibility of infection. Synthetic synchronization of the
estrus cycle has been performed in nonhuman primates via
exogenous progesterone therapy and such treatment results in
signiﬁcant thinning of the vaginal epithelium thereby enhancing
infection with SIV and SHIV isolates (Livingston et al., 2011; Marx
et al., 1996). Here we demonstrate that vaginal infection was
achieved in all four animals without the use of Depo-Provera.
Therefore, this virus will be suitable for performing low dose
multi-exposure challenges for testing efﬁcacy of microbicide
formulations in nonhuman primates as described elsewhere
(Kim et al., 2006; Otten et al., 2005; Parikh et al., 2009).
As noted with other SHIVs and in our earlier study (Smith
et al., 2010), plasma viremia in RT Env SHIV-infected macaques
dropped to undetectable levels within a few weeks. This is a
commonly seen trend with SHIVs compared to SIV isolates which
tend to establish a measureable set point for much longer.
Therefore this model is suitable primarily for microbicide and
PrEP related challenge studies where sterilizing infection is
examined. Rhesus macaques of Chinese origin were used for the
vaginal challenge experiments because of the availability of
female animals, and due to their extensive use in evaluating the
efﬁcacy of vaginal microbicides in prior studies. No attempt was
made to challenge rhesus macaques of Indian origin with RT Env
SHIV via the vaginal route, although it is expected that this
macaque species would be readily infected. Kinetics of decline
of plasma viremia was more apparent in IVAG-challenged maca-
ques, when compared to the IR- and IV-inoculated animals that
exhibited detectable viral loads for a longer period of time. This
difference in replication kinetics might be species-speciﬁc, as the
IVAG-challenged animals were of Chinese origin whereas IR- and
IV- challenged animals were of Indian origin. However, a larger
number of these macaque species would need to be challenged inorder to determine statistically signiﬁcant differences in the
replication kinetics of RT Env SHIV in Indian and Chinese rhesus
macaques. Regardless of the differences in replication kinetics
between these two species, which have been previously reported
for SIV (Ling et al., 2002; Reimann et al., 2005; Trichel et al., 2002)
modest cell-mediated immune responses to SIV Gag and minimal
responses to HIV-1 Env were detected in rhesus macaques at 78
and 112 day post-challenge, which was well into the chronic stage
of viral infection. Interestingly, no measurable response to HIV-1
RT was noted in these animals. Although all infected animals
clearly seroconverted and developed strong anti-Env antibody
responses beyond set point, the sera that were collected at
different time points post infection were non-neutralizing against
SHIV162P3, which encodes the autologous Env present in RT Env
SHIV (data not shown). Importantly, SGA and sequence analysis of
variants from the IVAG- and IR-infected macaques revealed
limited diversity when compared to both the expanded ConA-der-
ived challenge stock and the RT Env SHIV master stock. This low
level of genetic variation is consistent with the SGA ﬁndings in our
previous study (Smith et al., 2010) and is also in line with what is
typically observed during acute infection. Our results also demon-
strate that major genetic changes in this RT Env SHIV construct do
not need to occur to facilitate successful mucosal transmission and
subsequent establishment of peak viral load. Furthermore, com-
parison of the Con A-derived challenge stock to the RT Env SHIV
master stock showed that its genetic composition was not sig-
niﬁcantly affected by in vivo passages and in vitro expansion. The
maintenance of low genetic diversity during these passage and
expansion steps limits variations that could occur in laboratory-
expanded challenge stocks, thereby reducing potentially con-
founding factors during downstream data interpretation. Mito-
gen-speciﬁc effects on the in vitro expansion of RT Env SHIV are
also important to take into account, as demonstrated by the
observed difference in genetic heterogeneity between PHA-
derived and Con A derived virus stocks. Depending on the
objective of a given study, expanded stocks containing either
clonal or more heterogeneous populations could be generated.
In conclusion, the relative ease of in vivo transmission of this
dual RT Env SHIV virus via multiple routes of infection, and its
potent inhibition by entry and RT inhibitors either alone or in
combination makes it a useful tool to examine the efﬁcacy of such
drug combinations or drugs with dual activities in nonhuman
primate models. As the plasma viral loads in the infected animals
were shown to be controlled rapidly to undetectable levels during
the chronic stage of infection, this SHIV construct may not be
suitable for studying long-term pathogenesis of viral infection in
infected macaques, and it has limited applications in drug
therapeutic studies performed with chronically infected animals.
However, RT Env SHIV has speciﬁc applications for evaluating the
efﬁcacy of microbicide and PrEP regimens where sterilizing
protection from viral challenges is warranted.Materials and methods
Construction of RT Env SHIV
The dual RT Env SHIV was generated as previously described
(Smith et al., 2010). Brieﬂy, the virus was constructed in two
halves, with the 50 pVP1 plasmid being modiﬁed to replace the RT
gene from SIVmac239 with that from HIV-1 clone HXB2 by using
overlap extension PCR and standard cloning techniques. The
SHIV162P3 plasmid p160 containing the Clade B, CCR5-tropic
HIV-1 SF162 Env was used for the 30 half of the genome. Co-
transfection of 293T cells with these linearized 50 and 30 plasmids
yielded recombinant virus, that was further expanded in vitro in
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Env SHIV master stock.Expansion of RT Env SHIV by in vivo passage
RT Env SHIV stock was initially expanded in Chinese rhesus
macaques as described elsewhere (Smith et al., 2010). For in vivo
passage undiluted virus (1 ml) derived from Chinese rhesus
macaque PBMC was inoculated intravenously into an Indian
origin macaque (P237) and plasma viral load was monitored. At
peak viremia blood (10 ml) and bone marrow (10 ml) from the
infected macaque were infused into a second macaque (P241) and
the plasma viral load was monitored. Blood and bone marrow
from the second infected macaque was again injected intrave-
nously into a third naı¨ve macaque (P244) at peak infection and
the plasma viral load was monitored. At peak viral load, periph-
eral blood mononuclear cells (PBMC) were isolated by Ficoll
gradient centrifugation, depleted of CD8þT cells using anti-CD8
coated Dyna beads according to manufacturer’s instruction and
cultured for 72 h in RPMI medium containing rIL2 (16 ng/ml) and
either PHA (2.5 mg/ml) or ConA (2.0 mg/ml) at a density of 1106
cells/ml. The activated cells were washed free of mitogen and
cultured in an equal volume of RPMI 1640 medium containing
rIL2 for 3 days. Freshly cultured naı¨ve PHA- or ConA-activated
rhesus PBMCs (1106 cells/ml) were then added to the culture to
enhance virus expansion and the culturing was continued for
7–10 days. Every 3 days supernatant was tested for SIV p27 and
replenished with fresh medium by half medium change. Cell-free
supernatant was harvested when the p27 level reached 25 ng/ml,
ﬁltered and stored as 1 ml aliquots in the vapor phase of liquid
nitrogen. Infectious titer (TCID50) of the RT Env SHIV stocks was
determined both in rhesus PBMC and TZM-bl cells. Both PHA- and
ConA-derived virus stocks were used in RT and entry inhibitor
assays, while ConA-derived RT Env SHIV was utilized for subse-
quent IV, IR and IVAG challenges.
Infection assay to measure sensitivity of RT Env SHIV and RT SHIV to
reverse transcriptase and entry inhibitors
Maraviroc was obtained from the NIH AIDS Research and
Reference Reagent Program, whereas CMPD167, tenofovir and
dapivirine were provided by International Partnership for Micro-
bicides. RT SHIV used in these inhibition studies was prepared and
characterized as described before (Pal et al., 2009). Inhibitory
activity of these entry and RT inhibitors against RT Env SHIV and
RT SHIV was measured as a reduction in luciferase reporter gene
expression after a single round of infection in TZM-bl cells (NIH
AIDS Research and Reference Reagent Program). For this assay, RT
Env SHIV was incubated with different concentrations of test
compounds in triplicate in a total volume of 150 ml of DMEM
medium for 1 h at 37 1C in 96-well ﬂat-bottom culture plates.
Freshly trypsinized TZM-bl cells (10,000 cells in 100 ml DMEM
medium containing 75 mg/ml DEAE dextran) were added to each
well. One set of control wells received cells and virus (virus control)
and another set received cells only (background control). After
incubation for 48 h, 100 ml of lysate was transferred to 96-well
black plates (Costar) for measurement of luminescence using the
Bright-Glo Luciferase Assay System (Promega). Inhibitory activity
was measured as the concentration of antiviral at which the relative
luminescence units (RLU) were reduced by 50% compared to virus
control wells after subtraction of background RLUs.
For infection assay in rhesus PBMC, PHA-stimulated PBMC
(2107 cells) were preinfected by incubating with Con A-derived
RT Env SHIV (4040 TCID50) for 4 h. Cells were extensively washed
and cultured at 2105 cells per well in a 96-well plate, in the
presence of decreasing concentration of entry and RT inhibitors.Viral infection was quantitated by measuring SIV p27 protein in
the supernatant by antigen capture ELISA (ABL, Inc., Rockville,
MD) 7 to 10 days after infection.
Single genome ampliﬁcation (SGA) and sequencing
SGA was performed using previously published protocols and
cycling conditions (Salazar-Gonzalez et al., 2008). In vitro-
expanded RT Env SHIV or plasma isolates of RT Env SHIV were
subject to viral RNA extraction using a QIAamp viral RNA mini kit
(Qiagen, Valencia, CA, USA). Reverse transcription of RNA to cDNA
was performed as previously described (Smith et al., 2010).
Primary PCR for the ampliﬁcation of gag from RT Env SHIV cDNA
was done using the primers 878F-L 50-TGAGTACGGCTGAGT-
GAAGGCAGTAAG-30 and BL-R5 50-CTGCGGGATGTGGTATTCCTA-30,
followed by nested PCR with the primers 910F-L 50-AGGAACCAAC-
CACGACGGAGTGC-30 and 11R 50-TTTAACTTTTGGGCCATCCA-30.
Similarly, pol was initially ampliﬁed using the primers 2102F 50-
AGAAATGCTGACGGCTTGTC-30 and 4709R-L 50-TTGCCTGCCCATG-
TATAGCCTCTC-30, followed by second round PCR with primers 10F
50-ATTAATGGCAGAAGCCCTGA-30 and 4671R 50-TTATCACAGGTG-
TCTACTATCTGTCTGGCC-30. Primary and secondary PCR for ampli-
ﬁcation of full-length env and nef were performed using the
following primer pairs:
H2 SM-EF1 (6330) 50-CCTTGAGGGAGCAGGAGAACTCATTA-30
and 10469R 50-CAAGCAAGCGTGGAGTCACT-30, and 162p3InnerF
(6599) 50CTTCTTCCTGCCATAGGAGATGCCTAAGC-30 and 10392R
50-CTGCTAGTGCTGGAGAGAACCTC-30. A total of 20 amplicons/
gene were derived by SGA from each sample. The Dye Terminator
Cycle Sequencing (DTCS) quick-start sequencing kit and the CEQ
8000 system (both manufactured by Beckman Coulter, Fullerton,
CA, USA) were utilized to generate sequences from ampliﬁed PCR
products.
Sequencing analyses
Only chromatograms exhibiting single peaks, which indicate
the presence of a single viral variant (Salazar-Gonzalez et al.,
2008), were considered for further analysis. For each gene of
interest, the sequences of 20 amplicons were analyzed. Sequence
alignment and nucleotide translation were performed using
Vector NTI 10 (Invitrogen). Where indicated, the reference
sequence that was used for comparison was the consensus of
the RT Env SHIV master stock, or the virus isolate from the P244
(P3) vRNAþ plasma sample at peak viral load, or the ConA-der-
ived stock from in vitro expansion of P244 (P3) PBMC. All env
sequences were edited to span the highly variable V1–V5 region.
Pairwise sequence comparison and the generation of phylogenetic
trees by the neighbor-joining method were performed using
Geneious software (Version 5.5.3, Biomatters Ltd, Auckland,
New Zealand). Trees were assessed for reliability by analysis of
at least 100 bootstrap replicates. Genetic diversity of env V1–V5,
gag, pol and nef was determined by visual analysis of neighbor-
joining phylogenies and the Highlighter tool (http://www.hiv.lanl.
gov), and by considering Hamming distances.
Infection of rhesus macaques with RT Env SHIV via multiple routes
Both Indian and Chinese rhesus macaques (Macaca mulatta)
weighing 4–5 kg and virologically and immunologically negative
for type D retrovirus, SIV and simian T-lymphotropic virus (STLV)
were selected for this in vivo evaluation. The Animal Care and Use
Committee of Advanced BioScience Laboratories approved all
protocols used in this study. For the vaginal challenge, macaques
were sedated with ketamine-HCl (10 mg/kg) and placed in sternal
recumbency with their knees and hips ﬂexed. The posterior of
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abdomen, thus minimizing the potential for leakage of inoculum.
For rectal inoculation animals were sedated as described above.
For both vaginal and rectal challenge 1 ml of ConA-expanded
virus (2.02103 TCID50) was administered. Intravenous admin-
istration of virus was performed in sedated animals with 1 ml of
diluted ConA-expanded virus (250 TCID50).
Virological assays
Animals were bled periodically following viral challenge and
plasma viral RNA load was measured using a real-time nucleic-
acid-sequence-based ampliﬁcation assay (NASBA) to quantify SIV
RNA (Lee et al., 2010). This assay has a lower limit detection of 50
copies of SIV RNA. Additional blood samples were collected
periodically following challenge and CD4þT lymphocyte counts
quantitated by ﬂow cytometry, as described before (Cristillo et al.,
2007).
Immunological assays
ELISPOT assays were conducted by ex vivo stimulation of
PBMC from infected macaques using overlapping peptides of SIV
Gag, Env from SHIV162P3 and HIV-1 RT as described elsewhere
(Cristillo et al., 2008). For neutralization assay, SHIV162P3 (200
TCID50) was incubated with serial dilutions of heat inactivated
and ﬁltered sera from chronically infected macaques in duplicate
in a total volume of 50 ml of DMEM medium for 1 h at 37 1C in 96-
well plates. Freshly trypsinized TZM-bl cells (104) in 50 ml DMEM
medium containing 75 mg/ml DEAE dextran were added to each
well. One set of control wells received cells and virus (virus
control) and another set received cells only (background control).
After incubation for 48 h, 100 ml of lysate was transferred to 96-
well black plates (Costar) for measurement of luminescence using
the Bright-Glo Luciferase Assay System (Promega). Neutralization
titers are deﬁned as the dilution of serum or concentration of test
material at which the relative luminescence units (RLU) were
reduced by 50% compared to virus control wells after subtraction
of background RLUs.Acknowledgments
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